Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 2Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Post-operative Ileus 1Pancreatic Neoplasms 1Lung Neoplasms 1Gallbladder Neoplasms 1Disease 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Gastric Carcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 60palbociclib 37Trastuzumab 31Letrozole 26Immunohistochemistry 26Drug Therapy 24Anastrozole 24Radiotherapy 21Gene Expression Profiling 20Amplified Fragment Length Polymorphism Analysis 20Mastectomy, Segmental 19Biopsy 19Tamoxifen 18exemestane 17Interviews as Topic 17ribociclib 16Mastectomy 16Fulvestrant 16Paclitaxel 15Magnetic Resonance Spectroscopy 15Psychiatric Rehabilitation 14High-Energy Shock Waves 14Polymerase Chain Reaction 13Observation 13Microarray Analysis 13Capecitabine 13trastuzumab deruxtecan 12Neoadjuvant Therapy 12Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Breast Neoplasms × Defecation × Clear all
NCT05444647 2022-07-06

Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study

The First Affiliated Hospital with Nanjing Medical University

Unknown
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡